CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate
* CStone to acquire exclusive rights for development and commercialization outsideSouth Korea for LCB71, an ROR1 antibody drug conjugate * Agreement adds to CStone's pipeline a potential first-in-class/best-in-class drug candidate with monotherapy and combination applications for a range of c...
CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)
* CStone to out-license to EQRx exclusive rights to two late-stage immuno-oncology assets for development and commercialization outside ofGreater China * Agreement provides a pathway to bring CStone's sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1) to global patient communities by partnering ...
CStone Announces Completion of $200 million Share Sale to Pfizer
SUZHOU, China, Oct. 12, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announced today the completion of the Share Subscription Agreement through which an affiliate of Pfizer Inc. ("Pfizer", NYSE: PFE) subscribed for newly issued CStone shares at approximatelyUS$200 million (e...
CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab (CS1001) At 2020 CSCO Annual Meeting
* CS1001-201 study demonstrated an objective response rate (ORR) of 44.7%, a complete response (CR) rate of 31.6%, median overall survival (mOS) of 19.7 months and an one-year overall survival (OS) rate of 55.5% in patients with relapsed or refractory extranodal natural killer /T cell lymphoma ...
CStone Announces Preliminary Results from a Bridging Study of Avapritinib in Chinese Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors at the 2020 CSCO Annual Meeting
* Avapritinib has demonstrated strong anti-tumor activity in Chinese patients with PDGFRA D842V mutant GIST * Avapritinib was generally well tolerated in Chinese GIST patients, consistent with the safety profile demonstrated in global studies SUZHOU, China, Sept. 25, 2020 /PRNewswire/ -- CSton...
CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R/R ENKTL
SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- CStone Pharmaceuticals (SUZHOU) Co., Ltd. ("CStone", HKEX: 2616) today announced that the US Food and Drug Administration (FDA) has completed their review of the Investigational New Drug (IND) application for anti-PD-L1 monoclonal antibody sugemalimab ...
CStone Pharmaceuticals Reports Financial Results for the First Half of 2020
SUZHOU, China, Aug. 19, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, today reported recent business highlights and financial resu...
CStone submits new drug application for the targeted therapy avapritinib in Taiwan for the treatment of adults with advanced PDGFRA exon 18 mutant gastrointestinal stromal tumor
SUZHOU, China, March 27, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for avapritinib, a precision therapy being developed for the t...
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
SUZHOU, China, Jan. 24, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) recently announced that it has dosed the first patient inAustralia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with regorafenib, an...
CStone successfully hosted the first U.S. R&D Day in New York
* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical development, with a total of 13 on-going registrational trials. * The Company has implemented its pipeline strategy for early-stage candidates and combination therapy. With an established clinical d...
CStone successfully hosted the first U.S. R&D Day in New York
* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical development, with a total of 13 on-going registrational trials. * The Company has implemented its pipeline strategy for early-stage candidates and combination therapy. With an established clinical d...
CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma
SUZHOU, China, Jan. 8, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) announced that the first patient has been dosed in the Phase III GEMSTONE-304 study of the Company's anti-PD-L1 antibody CS1001 in combination therapy as first-line treatment in patients wit...
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia
SUZHOU, China, Dec. 12, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has recently received the approval from the Human Research Ethics Committee (HREC) in Australia, and the acknowledgement from Australia's Therapeutic Goods ...
CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST
SUZHOU, China, Dec. 11, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the on-going, global Phase III VOYAGER clinical trial of avapritinib, an investigational drug discovered by CStone's partner, Blueprint Medicines, has completed target ...
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
SUZHOU, China, Dec. 10, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) updated results from the CS1001-201 trial in a poster presentation at the 2019 American Society of Hematology (ASH) Annual Meeting. CS1001-201 trial is a single-arm, multicenter Phase II c...
CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial
SUZHOU, China, Dec. 6, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced the appointment of Ms.Shirley Zhao to the position of General Manager forGreater China and Head of Commercial. In this position, Ms. Zhao will be responsible for the commerci...
CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib
SUZHOU, China, Nov. 20, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the first patient has been dosed in the Phase I bridging registrational study of ivosidenib (TIBSOVO®) in China. This stand-alone trial is designed to validate the effi...
ASH 2019 | CStone's anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
SUZHOU, China, Nov. 7, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that an abstract on the CS1001-201 trial (Abstract #2833) was accepted by the 2019 American Society of Hematology (ASH) Annual Meeting and has been published online yesterday...
ESMO 2019: CStone presents pooled safety data from the Phase 1b trial of CS1001, demonstrating promising overall safety and tolerability
SUZHOU, China, Sept. 30, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) released pooled safety data from the Phase Ib (GEMSTONE-101) study of the Company's anti-PD-L1 antibody CS1001 in a poster presentation at the European Society of Medical Oncology 2019 Con...
2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors
SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced results from the microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) solid tumor cohort in the GEMSTONE-101 Phase Ib study of the Company's investigation...
